Últimas noticias sobre SSR Mining (NASDAQ:SSRM) Bolsa

SSR Mining

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

Male,Hand,Holding,Gold,Ingot,And,Fluctuating,Gold,Price,Chart

Equities

News

Commodities

Markets

GOLD

SSRM

USAU

El oro marca un nuevo récord histórico mientras los inversores apuestan por refugios ante tensiones comerciales crecientes.

Acciones de mineros de oro se disparan con tensiones comerciales entre EE. UU. y China

SSR Mining Inc

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm</a>

UBER

Uber Technologies To Acquire 85% Controlling Stake In Trendyol GO Online Meal And Grocery Delivery Business In Turkiye For ~$700M

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target

WIIM

DDOG

DDOG stock has given up its prior gain. Datadog shares were trading higher after the company reported better-than-expected Q1 results and raised its FY25 guidance.

Billionaire investor Bill Ackman isn't just writing a $900 million check to Howard Hughes Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) &#8211; he's rewriting the script.
In a move that caught Wall Street's eye, Pershing Square, backed mainly by Ackman himself, is investing in Howard Hughes at $100 a share &#8211; a 48% premium over its May 2 close of $67.47. The punchline? Ackman's not going for a full buyout. Instead, he's installing himself as executive chairman and bringing his trusted lieutenant Ryan Israel along as chief investment officer.
Related: <a href="https://www.benzinga.com/25/05/45199902/bill-ackman-strikes-deal-to-form-mini-version-of-berkshire-hathaway-a-free-money-generating-company-he-wouldnt-bet-against">Bill Ackman Aims To Mimic Buffett, Berkshire Blueprint With $900M Howard Hughes Bet</a>
For Ackman, this is more than just a financial play – it's about transforming Howard Hughes into a diversified holding company, with future acquisitions likely in industries like insurance. While the real estate game remains Howard Hughes's core, Ackman aims to breathe new life into the company, one strategic deal at a time.
JPMorgan analyst Anthony Paolone is bullish on the stock, calling this deal a transformational shift. The new agreement cuts Pershing's annual fees to a modest $15 million, down from the previous proposal's $60 million, while linking additional fees to actual equity growth. With a target price of $82, Ackman could earn $29 million – half of what the previous plan would have cost. But there's a catch: Howard Hughes's real estate assets remain tough to value, and the stock will likely continue to trade below its net asset value (NAV), pegged at $90 by JPMorgan.
So, while Ackman may have a playbook, will he be able to execute it? That's the $900 million question.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="633" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM.png" alt="" class="wp-image-902951" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM-300x232.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">Chart created using Benzinga Pro</a>
On the technical side, Howard Hughes is showing mixed signals. The stock price is currently $69.40, above the 8-day simple moving average (SMA) of $67.75, suggesting short-term bullish momentum. The 20-day SMA of $66.43 also signals a positive outlook.
The 50-day SMA of $71.34 and the 200-day SMA of $74.94 point to bearish pressure in the longer term. The Moving Average Convergence Divergence (MACD) indicator is at a negative 0.91, signaling a bearish outlook, while the Relative Strength Index (RSI) at 53.09 suggests a neutral stance.
In short, Howard Hughes is caught between bullish short-term signals and bearish longer-term pressure. To gauge the next move, traders will need to watch for a break above the 50-day SMA or a dip below the 200-day SMA.
Keep an eye on the stock as Ackman's strategy unfolds. The earnings report on May 7 will be the next key test.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45193861/3-stocks-warren-buffett-first-bought-24-years-ago-hint-apples-not-one-of-them">3 Stocks Warren Buffett First Bought 24 Years Ago (Hint: Apple&#8217;s Not One Of Them)&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Hedge Funds

Technicals

Previews

Trading Ideas

Bill Ackman's $900M Boost Could Lift Howard Hughes Stock Above Key Technical Barrier Ahead Of Q1 Earnings

Guidance

Embraer-Empresa Brasileira De Aeronautica

Embraer Affirms FY25 Sales Guidance Of $7.00B-$7.50B vs $7.34B Estimate

Biotech

Legal

General

WINT

Windtree Therapeutics Received Advice From Intellectual Property And FDA Experts; Istaroxime May Receive New Chemical Entity Designation; Istaroxime Has USPTO Issued Method Of Patent Providing Protection Until 2039 And Pedning Method Of Using Patent Providing Protection Until 2043

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $0.03 by 1433.33 percent. This is a 471.43 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $1.10 billion which missed the analyst consensus estimate of $1.18 billion by 6.63 percent. This is a 23.02 percent increase over sales of $896.60 million the same period last year.

Earnings

Earnings Misses

Embraer Q1 Adj. EPS $(0.40) Misses $0.03 Estimate, Sales $1.10B Miss $1.18B Estimate

As of May 6, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>)</h3>
<ul>
<li>Teekay will release their financial results for the first quarter after the closing bell on Wednesday, May 7. Analysts expect the company to report quarterly earnings at $1.15 per share on revenue of $144.85 million. The company's stock jumped around 23% over the past month and has a <a href="https://www.benzinga.com/quote/TNK">52-week high of $74.20</a>.</li>
<li>RSI Value: 73.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TNK Price Action: Shares of Teekay Tankers jumped 4.7% to close at $46.17 on Monday.</li>
<li>Edge Stock Ratings: 27.51 Momentum score with Value at 94.71. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/TNK"><img loading="lazy" decoding="async" width="491" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48.png" alt="" class="wp-image-902800" style="width:377px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48.png 491w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48-300x105.png 300w" sizes="(max-width: 491px) 100vw, 491px" /></a></figure>
<h3 class="wp-block-heading">Frontline Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</h3>
<ul>
<li>On April 22, Evercore ISI Group analyst Jonathan Chappell maintained Frontline with an Outperform rating and lowered the price target from $22 to $20. The company's stock gained around 24% over the past month and <a href="https://www.benzinga.com/quote/FRO">has a 52-week high</a> of $29.39.</li>
<li>RSI Value: 70.5</li>
<li>FRO Price Action: Shares of Frontline gained 3.9% to close at $17.79 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next:<a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

FOXO

FOXO Technologies Says Its Myrtle Recovery Centers Subsidiary Has Seen Over 400 Patients Since Aug. 2023

AMETEK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) and FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) today announced that they have entered into a definitive agreement under which AMETEK will acquire all outstanding shares of FARO Technologies common stock for $44 per share in cash, which represents an approximate 40% premium to FARO's closing price on May 5, 2025. The transaction values FARO at an enterprise value of approximately $920 million. The boards of directors of both companies have unanimously approved the transaction.
Founded in 1981 and headquartered in Lake Mary, Florida, FARO Technologies is a leading provider of 3D measurement and imaging solutions, including portable measurement arms, laser scanners and trackers, software solutions, and comprehensive service offerings. FARO's precision manufacturing and digital reality solutions serve a diverse range of end markets. The company has annual sales of approximately $340 million.

FARO

AMETEK And FARO Technologies Have Entered Into A Definitive Agreement Under Which AMETEK Will Acquire All Outstanding Shares Of FARO Technologies Common Stock For $44 Per Share In Cash, Or An Enterprise Value Of ~$920M

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $0.95 per share which missed the analyst consensus estimate of $0.99 by 4.04 percent. This is a 10.47 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $60.05 million which beat the analyst consensus estimate of $57.78 million by 3.94 percent. This is a 44.38 percent increase over sales of $41.59 million the same period last year.

Earnings Beats

Camden National Q1 Adj. EPS $0.95 Misses $0.99 Estimate, Sales $60.05M Beat $57.78M Estimate

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/amd/earnings">closing bell on Tuesday, May 6.</a>
Analysts expect the Santa Clara, California-based company to report quarterly earnings at 93 cents per share, up from 62 cents per share in the year-ago period. AMD projects to report quarterly revenue at $7.12 billion, compared to $5.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Advanced Micro Devices, on April 9, announced the new Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud C4D and H4D virtual machines (VMs), which fifth-generation AMD EPYC processors power.
AMD shares gained 1.8% to close at $100.59 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/amd/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Ruben Roy maintained a Buy rating and cut the price target from $162 to $132 on April 28, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Susquehanna analyst Christopher Rolland maintained a Positive rating and cut the price target from $150 to $135 on April 24, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Wedbush analyst Matt Bryson maintained an Outperform rating and slashed the price target from $150 to $115 on April 23, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Bernstein analyst Stacy Rasgon maintained a Market Perform rating and cut the price target from $125 to $95 on April 22, 2025. This analyst has an accuracy rate of 71%.</li>
<li>UBS analyst Timothy Arcuri maintained a Buy rating and lowered the price target from $175 to $155 on April 17, 2025. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="613" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png" alt="" class="wp-image-902688" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a> </li>
</ul>
Photo via Shutterstock

GOOG

GOOGL

Top Wall Street Forecasters Revamp AMD Motor Expectations Ahead Of Q1 Earnings

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy rating and announced a price target of $315. Workday shares closed at $248.34 on Monday. <a href="https://www.benzinga.com/quote/wday/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson initiated coverage on Broadridge Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Buy rating and announced a price target of $300. Broadridge Financial shares closed at $232.18 on Monday. <a href="https://www.benzinga.com/quote/br/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Matt Olney initiated coverage on FirstSun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with an Overweight rating and announced a price target of $44. Firstsun Capital Bancorp shares closed at $35.50 on Monday. <a href="https://www.benzinga.com/quote/fsun/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-1024x570.png" alt="" class="wp-image-903111" style="width:672px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Initiation

FSUN

WDAY

This Workday Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.73) by 10.96 percent. This is a 44.64 percent decrease over losses of $(0.56) per share from the same period last year.

VERA

Vera Therapeutics Q1 EPS $(0.81) Misses $(0.73) Estimate

<a href="https://www.globenewswire.com/Tracker?data=bU_w34dgBvOq2j_Ai4IkIyvGeKLYYW3GNkjP-nGsC-2e2AY-Gv-G3xxySQLifClFaoUm0kd9V5G5AaGj6yWjgAG6V9aJz2xiGAcnviE2CRy2_IA2tON7BnEpHftb9W5bTFXJOotUhJJQ9tJdKvWoVQLWK-R3wLN1uIaUnhXJDG3JFyVl7wKdxfwtqvd5tf5K">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that data from the company's Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in newly diagnosed patients with advanced epithelial ovarian cancer will be published in the peer-reviewed journal Gynecologic Oncology.
The review of full data, entitled: OVATION-2: A Randomized Phase I/II study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 gene therapy) with Neo/Adjuvant Chemotherapy in Patients Newly- Diagnosed with Advanced Epithelial Ovarian Cancer, is scheduled for publication on June 3, 2025.
As previously announced, data from the OVATION 2 study will also be reviewed in an oral presentation during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2025 in Chicago, Illinois. Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David &amp; Lynn Mutch Distinguished Professor of Obstetrics &amp; Gynecology, Director of&nbsp;Gynecologic Oncology Clinical Research&nbsp;at&nbsp;Washington University School of Medicine, is lead author on the publication and will lead the discussion in the oral presentation at the ASCO meeting.
"We are very pleased that the data from our OVATION 2 study will be presented in the highly esteemed peer-reviewed journal Gynecologic Oncology and in an oral presentation at the ASCO meeting," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "Having our data presented in two of the premier global platforms in gynecologic oncology underscores both the critical need to develop new therapies to treat ovarian cancer and the strength and potential of IMUNON's TheraPlas&#xAE; platform technology."
About the Phase 2 OVATION 2 Study
OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare NACT plus IMNN-001 versus standard-of-care NACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2&nbsp;in addition to NACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response.

IMNN

IMUNON Announces Data From Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 In Combination With Neoadjuvant Chemotherapy In Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer. Will Be Published In Gynecologic Oncology

INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland
SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=3606414742&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=2934215094&amp;u=https%3A%2F%2Fwww.sakk.ch%2Fen&amp;a=SAKK">SAKK</a> ("SAKK"), a&nbsp;decentralized&nbsp;academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Medicines Agency ("EMA") has authorized the initiation of the INVINCIBLE-4 (SAKK 66/22) ("INVINCIBLE-4 Study") (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=2042607023&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4227864-1%26h%3D1711039643%26u%3Dhttps%253A%252F%252Fwww.clinicaltrials.gov%252Fstudy%252FNCT06358573%253Fterm%253DINT230-6%2526rank%253D4%26a%3DNCT06358573&amp;a=NCT06358573">NCT06358573</a>)&nbsp;in France in collaboration with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=1426838703&amp;u=https%3A%2F%2Fwww.unicancer.fr%2Fen%2F&amp;a=Unicancer">Unicancer</a>.
The INVINCIBLE-4 Study is a randomized open-label, multicenter study to determine the clinical activity, safety, and tolerability of INT230-6 in patients with early-stage, operable triple-negative breast cancer ("TNBC") who undergo standard of care neoadjuvant immunochemotherapy ("SOC") treatment and SOC alone. The primary endpoint is pathological complete response ("pCR") in the primary tumor and affected lymph nodes. Patients will be randomized one-to-one to receive a regimen of either two doses of INT230-6 followed by SOC, which consists of pembrolizumab, anthracyclines, carboplatin, cyclophosphamide, and paclitaxel (i.e., the Keynote-522 regimen), or the SOC alone. The study is already recruiting patients in Switzerland and is expected to enroll 54 patients.
 &nbsp;

INTS

Intensity Therapeutics and SAKK Secure EMA Approval To Initiate INVINCIBLE-4 Cancer Trial In France In Collaboration With Unicancer

Transaction adds proven HVAC solutions leader to ConnectM's expanding constellation of brands
MARLBOROUGH, Mass., May 6, 2025 /PRNewswire/ -- ConnectM Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) ("ConnectM" or the "Company"), a high-growth technology company powering the next generation of electrified equipment, mobility, and distributed energy, today announced the acquisition of all the assets of Air Temp Service Co. ("Air Temp"), a leading provider of heating and cooling solutions in New Jersey, in exchange for 1.5 million shares of ConnectM common stock.

CNTM

ConnectM Announces Acquisition Of Air Temp, Strengthening Owned Service Network, In Exchange For 1.5M Shares Of ConnectM Common Stock.

INMD

InMode Awarded Injunction And Damages For Counterfeit Sales Of Morpheus8 Radio Frequency Microneedling Devices And Needle Cartridges

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) affirms FY2025 sales outlook from $153.00 million-$163.00 million to $153.00 million-$163.00 million vs $157.27 million estimate.

HRTX

Heron Therapeutics Affirms FY2025 Sales Guidance of $153.00M-$163.00M vs $157.27M Est

Press Releases

SSR Mining Announces the Acquisition of the Cripple Creek & Victor Gold Mine From Newmont

SSR Mining Celebrates 5 Million Ounces of Gold Production From Marigold

SSR Mining Announces Expert Findings on Cause of the Çöpler Incident

SSR Mining to Announce Fourth Quarter and Full-Year 2024 Consolidated Financial Results on February 18, 2025

SSR Mining Appoints Laura Mullen to Board of Directors

SSR Mining Reports Fourth Quarter and Full-Year 2024 Results

SSR Mining to Voluntarily Delist From ASX

SSR Mining Announces Closing of Cripple Creek & Victor Acquisition

SSR Mining Provides 2025 Operating Guidance

SSR Mining to Announce First Quarter 2025 Consolidated Financial Results on May 6, 2025

Comments

SSR Mining

Noticias

Últimas noticias sobre SSR Mining (NASDAQ:SSRM) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL